Table 1.
Characteristics of participants in this study
| Parameters | All participants | Participants with APOE genotype data | ||||
|---|---|---|---|---|---|---|
| Total (n = 452) | Aβ+NfL+ group (n = 46) | Other participants† (n = 406) | Total (n = 410) | Aβ+NfL+ group (n = 39) | Other participants† (n = 371) | |
| Age (year), mean (SD) | 76 (5) | 78 (5)** | 76 (5) | 76 (5) | 78 (5)** | 76 (5) |
| Female, n (%) | 268 (59%) | 23 (50%) | 245 (60%) | 224 (55%) | 19 (49%) | 224 (60%) |
| Participants with plasma biomarkers measured in the first year, n (%) | 420 (93%) | 44 (96%) | 376 (93%) | 382 (93%) | 37 (95%) | 345 (93%) |
| Initial body mass index, mean (SD) | 26.4 (4.0) | 25.9 (3.8) | 26.5 (3.9) | 26.4 (3.8) | 25.6 (3.1) | 26.5 (3.9) |
| Initial CCS, mean (SD) | 0.07 (0.79) | − 0.25 (0.70)** | 0.10 (0.79) | 0.10 (0.77) | − 0.20 (0.71)* | 0.14 (0.78) |
| Initial MMSE, mean (SD) | 27.8 (1.9) | 27.5 (1.7) | 27.9 (1.9) | 27.9 (1.8) | 27.7 (1.6) | 27.9 (1.8) |
| Initial gait speed (m/s), mean (SD) | 1.0 (0.2) | 1.0 (0.3) | 1.0 (0.2) | 1.0 (0.2) | 1.0 (0.3) | 1.0 (0.2) |
| Initial chair-stand time (s), mean (SD) | 12.1 (4.3) | 12.9 (4.0) | 12.0 (4.4) | 12.0 (4.3) | 12.9 (4.2) | 11.9 (4.3) |
| Aβ42/Aβ40 ratio, mean (SD) | 0.114 (0.018) | 0.097 (0.010)** | 0.116 (0.018) | 0.113 (0.018) | 0.096 (0.010)** | 0.115 (0.018) |
| NfL (pg/ml), mean (SD) | 86.65 (74.09) | 160.35 (137.01)** | 78.30 (57.79) | 85.70 (75.50) | 162.55 (143.15)** | 77.62 (59.23) |
*p < 0.05, **p < 0.01 when compared Aβ+NfL+ group with other participants
†Other participants without Aβ+NfL+ condition